Kuss M, Heidrich H, Koettgen E
Institut für Laboratoriumsmedizin und Pathobiochemie, Medizinischen Fakultät Charité, Humboldt-Universität zu Berlin, Germany.
Vasa. 2003 Aug;32(3):145-8. doi: 10.1024/0301-1526.32.3.145.
The study was designed to evaluate if there is any evidence of a hyperfibrinolytic bleeding-risk under systemic treatment with prostaglandin E1 (PGE1) of patients with peripheral arterial disease (PAD).
The in vivo effect of PGE1 on the fibrinolytic and hemostatic process was tested on 15 patients before and after treatment with Alprostadil for 21 days using D-dimers (DD), fibrinogen, prothrombin time (PT), partial thromboplastin time (PTT), antithrombin (AT), ProC-Global, plasminogen, plasminogen activator inhibitor activity (PAI), alpha 2-antiplasmin, coagulation factor XII, basal and activated fibrinolytic capacity (fib. cap.).
There was no significant difference in DD, fibrinogen, PT, PTT, AT, ProC-Global, plasminogen, PAI, alpha 2-antiplasmin, coagulation factor XII, basal and activated fibrinolytic capacity observed after the treatment.
Summarizing this study there is no hyperfibrinolytic bleeding-risk after the systemic therapy with Alprostadil to be expected.
本研究旨在评估接受前列腺素E1（PGE1）全身治疗的外周动脉疾病（PAD）患者是否存在高纤溶出血风险的证据。
使用D-二聚体（DD）、纤维蛋白原、凝血酶原时间（PT）、部分凝血活酶时间（PTT）、抗凝血酶（AT）、ProC-全球、纤溶酶原、纤溶酶原激活物抑制剂活性（PAI）、α2-抗纤溶酶、凝血因子XII、基础和激活的纤溶能力（fib. cap.），对15例患者在接受前列地尔治疗21天前后进行PGE1对纤溶和止血过程的体内作用测试。
治疗后观察到的DD、纤维蛋白原、PT、PTT、AT、ProC-全球、纤溶酶原、PAI、α2-抗纤溶酶、凝血因子XII、基础和激活的纤溶能力无显著差异。
总结本研究，接受前列地尔全身治疗后预计不存在高纤溶出血风险。
